期刊
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
卷 32, 期 4, 页码 527-540出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0031-1283289
关键词
Vaccine; parainfluenza virus; metapneumovirus; respiratory syncytial virus; clinical trial; clinical development
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据